Most Popular Medicines for Diabetes and Obesity Also Protect Kidneys

Antidiabetic drugs, which also play an active role in reducing appetite and weight loss, also have positive effects for kidney protection, indicates a study published Lancet “Diabetes and endocronology”.

The study represents the largest and most comprehensive analysis yet seven drugsincluding semaglutide (also known as Ozempic or Vegovi), dulaglutide (Trulicity), and liraglutide (Victoza).

The effect of these drugs on chronic kidney disease has been poorly studied, and the team analyzed their effect on renal and cardiovascular outcomes, concluding that they have significant benefits

in people with and without diabetes.

These drugs, compared to placebo, reduced the risk renal failure in 16% and worsening renal function in 22% (determined by a decrease in estimated glomerular filtration rate). Co-reduces the risk of kidney failure, worsening kidney function, and death from kidney disease. was 19%.

A team led by Australian scientists conducted a meta-analysis 11 clinical studies involving 85,373 people. (67,769 with type 2 diabetes and 17,604 with overweight or obesity and cardiovascular disease but without diabetes).

Originally developed to treat diabetes, GLP-1 receptor agonist drugs mimic the action of a hormone called glucagon-like peptide 1, which stimulates insulin production and lowers blood sugar levels.

It later turned out that these drugs effective treatments for obesity

as they slow down digestion, increase the feeling of fullness and reduce the feeling of hunger.

The analysis also confirmed previous findings that protect the health of the cardiovascular system, with a 14% reduction in the risk of death from this cause, as well as non-fatal myocardial infarction and non-fatal stroke compared with placebo. All-cause mortality was 13% lower among patients treated with GLP-1 receptor agonists, notes Lancet “Diabetes and endocronology”.

Lead author Professor Sunil Badwe, a senior lecturer at the George Institute for Global Health and the University of New South Wales in Sydney, said the study adds to current knowledge of this class of drugs in key areas, including benefits in people with chronic kidney disease, as well as in people with with or without chronic kidney disease. diabetes. According to the scientist, this suggests that these drugs “play a key role in renoprotective and cardioprotective treatment

patients with common diseases such as type 2 diabetes, overweight or obesity with cardiovascular disease or chronic kidney disease.